Biotech News

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

Esperion Therapeutics (ESPR)Esperion Therapeutics2026-03-31 12:01 ESTConference / presentation

ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25 th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The live webcast can be accessed on the investor and media

Related news

ESPREsperion Therapeutics2026-05-26 12:00 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-05-14 20:30 EST

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

View all latest news

Esperion Therapeutics

Oral Cardiometabolic Medicines Esperion Therapeutics develops and commercializes oral therapies for cardiovascular risk reduction and is expanding toward rare hepatic and renal diseases. Its scientific foundation is inhibition of ATP citrate lyase. Bempedoic Acid Franchise NEXLETOL and NEXLIZET are once-daily, non-statin...

Recent company news

ESPREsperion Therapeutics2026-05-26 12:00 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-05-14 20:30 EST

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPREsperion Therapeutics2026-05-13 12:00 EST

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

ESPREsperion Therapeutics2026-05-01 11:00 EST

Esperion to be Acquired by ARCHIMED

ESPREsperion Therapeutics2026-04-23 12:00 EST

Esperion to Report First Quarter 2026 Financial Results on May 7

Stock data

Close: 3.18 USD
Market cap: 808.34M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States